Episode 200 - October 23, 2026

What It Covers

Biotech Hangout's 200th episode, recorded October 23, 2026, brings together seven co-hosts and Silence Therapeutics former CEO Ali Mortazavi to examine Moderna's cancer vaccine stock volatility, the Merck KGAA acquisition of Silence Therapeutics for $1.3 billion, bearish biotech market dynamics, pharma CEO social media engagement, and five-year industry retrospectives from veteran operators and investors.

Key Questions Answered

• •Moderna valuation context: Moderna's market cap reached nearly $100 billion before the cancer vaccine data leak, surpassing Sanofi at $90 billion despite only $2.2–2.3 billion in annual revenue. When analyzing biotech stock moves, measure from the original trial success announcement rather than the prior day's price — doing so reveals the stock remained well above pre-announcement levels, making "crash" headlines misleading and context-dependent.
• •Options distortion in biotech markets: Retail traders holding short-dated options on acquisition targets like Abivax systematically distort price discovery and public sentiment. Because time premium erodes continuously, options holders need stocks to move immediately or face total loss — creating panic on normal pullbacks. Investors tracking sector health should monitor options-to-stock ownership ratios as a sentiment distortion signal, separate from fundamental analysis.
• •Degrossing as a structural market risk: Long-short platform funds, which have not had a down year in roughly a decade, now represent enough capital in biotech to cause sector-wide repricing through degrossing events unrelated to fundamentals. When heavily shorted names like Iovance and Twist spike, forced selling of long positions follows. Operators and investors should factor fund-flow technicals alongside data readouts when interpreting sudden sector-wide valuation swings.
• •China licensing as pharma's pipeline alternative: Roche, Gilead, and Eli Lilly each completed China-sourced licensing deals in the same week — Gilead paying $1.3 billion upfront for an oral IL-23 peptide. Pharma companies are increasingly bypassing US biotech acquisitions by licensing directly from Chinese biotechs. Biotech executives should monitor whether the US Treasury's proposed investment restrictions, currently in public comment, will accelerate this trend by penalizing venture-backed Chinese startups more than direct pharma licenses.
• •Silence Therapeutics turnaround blueprint: Ali Mortazavi rebuilt Silence Therapeutics from a £5 million market cap by abandoning a failing oncology program, pivoting from lipid nanoparticles to GalNAc delivery after benchmarking Alnylam, and taking a 10% stake in Arrowhead at a 70% discount to cash. The eventual $1.3 billion Merck KGAA acquisition at a 130% premium was driven primarily by divisiran targeting polycythemia vera — an indication switch made by a subsequent management team, illustrating that platform pivots compound across leadership generations.
• •Pharma CEO direct social media engagement: Eli Lilly CEO Dave Ricks posting unfiltered content on X without legal or communications review is cited as a model for rebuilding public trust in pharma. Brad Lunkar confirmed firsthand that Ricks writes his own posts. Given that pharma ranks among the most distrusted industries publicly, executives who demonstrate technical knowledge and personal authenticity on social platforms can shift perception more effectively than traditional corporate communications — and the CEO of the largest pharma company doing so removes compliance objections for others.